Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stannsoporfin for Hyperbilirubinemia in Term and Near-Term Infants
NCT02685137Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- May 2002
- Primary completion
- Mar 2003
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of stannsoporfin in hyperbilirubinemia, jaundice, sponsored by Mallinckrodt Pharmaceuticals. Started May 2002; status: completed.
02
Drugs
stannsoporfin
03
Conditions
hyperbilirubinemiajaundice
Beyond the preview
Go deeper on NCT02685137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685137.